Transfusion最新文献

{"title":"Identification of a novel variant c.102C>G (p.Tyr34*) in the ABO*B.01 allele.","authors":"Yachun Sun, Huixing Zhou, Xinyan Long, YunPing Xu","doi":"10.1111/trf.70397","DOIUrl":"https://doi.org/10.1111/trf.70397","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stacking platelet bags: A practical storage configuration for maintaining platelet quality during cold storage.","authors":"Janhavi Mahajan, Pearl Lei, Christopher Roan, Matthew P Padula, Denese C Marks, Lacey Johnson","doi":"10.1111/trf.70428","DOIUrl":"https://doi.org/10.1111/trf.70428","url":null,"abstract":"<p><strong>Background: </strong>As cold-stored platelets (CSPs) are being integrated into clinical practice, it is necessary to determine the storage practices that best support platelet quality while remaining operationally feasible. Platelet components are traditionally stored at room temperature, in a single layer, to facilitate gas exchange. The reduced metabolic activity of CSPs may allow for the storage of platelet bags in different configurations, offering improved space efficiency in blood bank refrigerators.</p><p><strong>Methods: </strong>Matched apheresis platelets (n = 8) in 40% plasma/60% PAS-E (SSP+) were refrigerated (2-6°C) in one of the following storage configurations: single layer (control), stored upright, or stacked flat. In vitro quality parameters were assessed at defined intervals over storage for 22 days.</p><p><strong>Results: </strong>Visible aggregates were identified in 75% of components that were stored upright between days 15 and 22, while no aggregates formed in control or stacked components during the storage period. Platelet components stored upright were more activated at maximal expiry, with greater loss of platelet glycoproteins (GPIbα and GPVI), and an increase in activation markers (P-selectin, annexin-V, and CD61⁺/annexin-V⁺ extracellular vesicles). Comparatively, no significant differences in platelet activation markers were observed in stacked platelets at the end of storage compared to controls. No differences in the metabolic or functional capacity of CSPs were observed, regardless of storage configuration.</p><p><strong>Conclusions: </strong>Platelet components stored upright were more activated and prone to aggregate formation over 22 days of storage. In contrast, stacking is a practical storage option that preserves platelet quality while minimizing space requirements in refrigerators and cool rooms.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel Colton null allele in a Palestinian family.","authors":"Maïlis Lauwers, Morgan Gueuning, Philippe Akiki, Gian Andri Thun, Isabelle Ruth, Capucine Hyon, Hanane El Kenz, Stefan Meyer","doi":"10.1111/trf.70399","DOIUrl":"https://doi.org/10.1111/trf.70399","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The transformative power of artificial intelligence and machine learning in blood banking/transfusion medicine: A vein-to-vein approach from blood collection to transfusion services: On behalf of the AABB Foundation.","authors":"Ruchika Goel, Sheharyar Raza, W Alton Russell, Jansen Seheult, Tho D Pham, Angelo D'Alessandro, Rounak Dubey, Celina Montemayor, David Daniel, Cliff Numark, Brian Custer, Jason Sapia, Tony Casina, Jerry Holmberg, Aaron Tobian, Na Li","doi":"10.1111/trf.70418","DOIUrl":"https://doi.org/10.1111/trf.70418","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI)/machine learning (ML) are poised to transform transfusion medicine across the vein-to-vein continuum, from donor recruitment to recipient outcomes. Large datasets generated from millions of donations and transfusions create opportunities for predictive modeling, precision medicine, improved safety, and operational efficiency. This review outlines key applications of AI in blood banking and transfusion medicine using a comprehensive vein-to-vein framework.</p><p><strong>Methods: </strong>The review synthesizes perspectives from blood services and hospital-based transfusion practices. Applications are discussed across donor recruitment, collections, testing, inventory management, hospital transfusion services, and education. Finally, AI safety, including ethical, regulatory, privacy, and implementation challenges, is addressed. This is a narrative, non-exhaustive review; given the rapidly evolving pace of AI/ML capabilities, this synthesis should be interpreted as a framework for ongoing surveillance rather than a fixed inventory of applications.</p><p><strong>Results: </strong>Donor-focused applications include personalized recruitment, individualized iron management, and fairness auditing to reduce inequities. In supply chain operations, ML can improve demand forecasting, minimize waste, and optimize inventory. Federated learning may support multi-institutional collaboration without sharing raw data. Omics and genomic applications can enable high-throughput analysis, phenotype prediction, and precision transfusion support for rare blood types and alloimmunized patients. In hospitals, AI can augment hemovigilance by identifying/predicting adverse transfusion reactions, while large language models and retrieval-augmented generation may enhance decision support, patient blood management, and education through adaptive learning.</p><p><strong>Conclusion: </strong>AI holds substantial promise to improve transfusion safety, efficiency, equity, and sustainability. Realizing this potential will require robust governance, model validation across diverse populations, privacy safeguards, bias mitigation, reproducibility, regulatory oversight, and human-in-the-loop implementation.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donor age is the major determinant of low-level blood lead burden in the REDS recalled donor cohort.","authors":"Daniel Stephenson, Travis Nemkov, Mars Stone, Steve Kleinman, Gregory R Keele, Grier P Page, Philip J Norris, Michael P Busch, Angelo D'Alessandro","doi":"10.1111/trf.70427","DOIUrl":"https://doi.org/10.1111/trf.70427","url":null,"abstract":"<p><strong>Background: </strong>Donated blood is a biological product whose molecular composition is influenced by donor exposures, including environmental toxicants such as heavy metals. Among these, lead is particularly relevant because no exposure level is considered completely without risk. Most circulating lead partitions into red blood cells (RBCs), and transfused RBC units can increase blood lead levels in vulnerable recipients. Whether donor lead burden reflects donor biology and associates with storage phenotypes remains unclear.</p><p><strong>Study design and methods: </strong>We analyzed 638 donors from the REDS donor study. Lead was measured by inductively-coupled plasma mass spectrometry and linked to donor demographics, donation frequency, end-of-storage hemolysis phenotypes, and RBC multi-omics features. Multi-omics associations were assessed by Spearman correlation and repeated using partial Spearman correlations adjusted for donor age, with false-discovery-rate correction across all tested features.</p><p><strong>Results: </strong>Lead levels ranged from 0.14 to 8.56 μg/dL. Donor age was the dominant correlate of lead (rho = 0.51, p < 1 × 10^-4), whereas BMI showed only a weak inverse association, despite its positive relationship with age in the cohort. Lead did not differ by sex, and frequent donation (>9 donations in the prior 24 months) was not associated with lower lead levels. At day 42, lead associated with 53 and 5 of 3468 multi-omics features in unadjusted and adjusted analyses, respectively.</p><p><strong>Conclusion: </strong>Low-level donor lead burden is strongly age-dependent. These findings identify donor age as a major determinant of the RBC lead exposome and highlight candidate age-independent features for further mechanistic study.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How do I create a cost structure for cellular therapy laboratory services supporting clinical trials?","authors":"Monica S Klein, Darcie J Radel, Becky D Kidd, Jeffrey L Winters, Timothy D Wiltshire, Allan B Dietz, Eapen K Jacob","doi":"10.1111/trf.70420","DOIUrl":"https://doi.org/10.1111/trf.70420","url":null,"abstract":"<p><strong>Background: </strong>The rapid growth of FDA-licensed and clinical trial cell and gene therapy products is causing significant growing pains for laboratories onboarding and processing these products for clinical use. While clinical programs have traditional and supplemental reimbursement models, many services provided by the laboratories are not directly reimbursed. Compounding this issue is the increasing diversity and complexity of products with unique processing requirements leading to resource-intensive workflows.</p><p><strong>Study design and methods: </strong>Our institution developed a three-tiered cost structure for services provided by the cellular therapy laboratory billed to industry-sponsored, externally manufactured clinical trials based on the level of start-up and per product handling complexity. A list of tasks and time required to complete the tasks was recorded to account for the complexity of the specific trial. This data was used to determine the total cost billed to onboard and carry out cell processing and handling tasks by the cellular therapy laboratory to the principal investigator of the clinical trial.</p><p><strong>Results: </strong>Our tiered fee structure enabled a more accurate accounting of laboratory personnel time based on the complexity of the clinical trial products, enabling our laboratory to recoup necessary costs.</p><p><strong>Conclusion: </strong>A tiered fee structure corresponding to higher levels of onboarding and administrative complexities can more accurately estimate costs to enable cell processing laboratories to remain financially sustainable and continue to deliver cell and gene therapy products to patients.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No difference in alloimmunization of pregnant adults with sickle cell disease exposed to chronic versus on-demand transfusions: A two-center retrospective cohort study.","authors":"Clare Zarka, David Daniel, Vinal Menon, Sacha Choupa, Macy L E Gatti, Amy Luo, Kevin Kuo, A Kinga Malinowski, Sophie Lanzkron, Nadine Shehata, Lydia H Pecker","doi":"10.1111/trf.70423","DOIUrl":"https://doi.org/10.1111/trf.70423","url":null,"abstract":"<p><strong>Background: </strong>Pregnant people with sickle cell disease (SCD) experience high morbidity and mortality, even when RBC transfusion is safe and available. There is a lack of consensus on transfusion use partly due to concern for alloimmunization. This study examined alloimmunization in SCD pregnancies managed with chronic transfusion therapy (CTT) versus on-demand transfusion (ODT). A secondary aim was to quantify the proportion of SCD pregnancies that met guideline indications for CTT that received CTT in pregnancy.</p><p><strong>Study design: </strong>This is a two-center, retrospective study of pregnancy in SCD over two decades. We compared alloimmunization between those who received CTT versus ODT by examining the Sickle Cell Pregnancy and Reproductive Knowledge Syndicate database. A secondary analysis applied American Society of Hematology (2020) and/or British Society for Haematology (2021) criteria for CTT in pregnancy to calculate guideline compliance.</p><p><strong>Results: </strong>Among 145 subjects, 26 received CTT and 119 received ODT. Alloimmunization incidence was 4%, with no significant difference by transfusion group (1/26 CTT vs. 5/119 ODT, p = 1.0). Five ODT subjects became alloimmunized (5/46). One CTT subject was alloimmunized (1/26) after receiving an unplanned ODT. Of all pregnancies, 87% met ASH criteria and 65% met BSH criteria for CTT, while 20% received CTT.</p><p><strong>Discussion: </strong>For patients with SCD in pregnancy, CTT may not pose a greater alloimmunization risk than ODT. CTT may be underutilized for SCD in pregnancy. Our study is limited by incomplete data and variable antigen matching practices. Prospective research will help establish the appropriate role of CTT in SCD pregnancies.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Umbilical cord red blood cell transfusions in very premature neonates: A physiologically aligned transfusion strategy.","authors":"Satyam Arora, Ruchika Goel, Jip van Daelen, Elise J Huisman, Cassandra D Josephson, Luciana Teofili","doi":"10.1111/trf.70422","DOIUrl":"https://doi.org/10.1111/trf.70422","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A distinctive RhD serologic phenotype expressed by p.Glu233Lys RHD alleles DV type 5 and DAU4 in microplate agglutination RhD typing.","authors":"Vidyadhari Karne, Mark J Jedrzejczak, Paul F Lindholm, Glenn Ramsey, Jay P Hudgins","doi":"10.1111/trf.70408","DOIUrl":"https://doi.org/10.1111/trf.70408","url":null,"abstract":"<p><strong>Background: </strong>In patients with variant RhD phenotypes, serologic reactions for partial RHD genotypes are indistinguishable from other variants.</p><p><strong>Study design and methods: </strong>In two US transfusion services, patients were typed for RhD by automated microplate RhD typing (Werfen, Norcross, GA) using two directly agglutinating IgM anti-D reagents, MS201 (epitope RhD (epD) 6.1) in Series 4 (Anti-D4) and TH-28 (epD6.4) in Series 5 (Anti-D5). For weak or discrepant RhD typing, we performed a RHD DNA microarray (RHD BeadChip, Werfen, Norcross, GA). For hemi- or homozygous c.697G>A (rs1053359), we obtained c.1136C>T (rs61740966) testing (New York Blood Center) to distinguish DV type 5 (DV.5) from DAU4 (c.1136T). We retrospectively examined previous cases with negative-weak anti-D4 and strong anti-D5 reactions for correlation with either DV.5 or DAU4 genotypes.</p><p><strong>Results: </strong>Eight of 442 patients with weak or discrepant RhD phenotypes (1.8%) had 0-1+ anti-D4, 3-4+ anti-D5 phenotypes. They were the only 8 patients with c.697G>A (correlation p < 0.0001, Fisher's exact test). Two had DV.5 (Hispanic, Armenian), 5 had DAU4 (4 Black, 1 Other), and 1 was not tested for c.1136 (Black). None had anti-D.</p><p><strong>Discussion: </strong>DV.5 and DAU4 alleles express disruptive p.Glu233Lys and are associated with hemolytic anti-D. Microplate RhD typing with decreased IgM anti-D4 reactions did not associate DV.5 and DAU4 with alloimmunization but indicated increased risk of anti-D alloimmunization. Similar epD6.1-weak, epD6.4-strong RhD reactions were observed in 10 DV.5 patients using automated microcolumn typing. Development of anti-D reagents detecting patients with other partial RHD genotypes beyond DVI is desirable.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring and feedback using data in transfusion medicine: A study of practices from the BEST Collaborative.","authors":"Ryan A Metcalf, Allison Mo, Sandra K White, Gustavo C Duarte, Nancy M Dunbar, Katie Hands, Anil K Panigrahi, Jessica L Poisson, Nabiha H Saifee, Hua Shan, Erica M Wood, Michael F Murphy, Simon J Stanworth","doi":"10.1111/trf.70316","DOIUrl":"10.1111/trf.70316","url":null,"abstract":"<p><strong>Background: </strong>It is imperative that health systems monitor transfusion practice quality and implement improvements when evidence-based practice gaps are identified. Despite the importance of data-driven quality activities, little is known about approaches employed by hospitals. This study aimed to describe strategies used by hospitals to acquire, analyze, and apply transfusion-related quality data.</p><p><strong>Study design and methods: </strong>A pre-piloted survey was developed by the core team, and Biomedical Excellence for Safer Transfusion (BEST) Collaborative attendees of meetings were invited to participate. Topics spanned five domains: hospital characteristics, data acquisition, quality metric prioritization, data analysis/visualization, and feedback processes. Responses were summarized to identify patterns and variation across institutions.</p><p><strong>Results: </strong>Nine hospitals of varying size, specialty mix, and transfusion volumes from three continents participated. Most transfusion services acquired transfusion data from both the electronic health record and the laboratory information system (6/9, 67%). Although all sites tracked the number of transfusions, there was wide variation in other metrics prioritized. Transfusion appropriateness was prioritized by 7 of 9 centers, but few reported monitoring antifibrinolytic agent use (2/9, 22%), anemia management (4/9, 44%), and consent (2/9, 22%). All hospitals performed some form of data analysis, but chart/table types and functionalities differed. Feedback was typically provided by transfusion medicine specialists or hematology, but frequency and means differed between sites.</p><p><strong>Discussion: </strong>This descriptive study highlights significant variation in how selected hospitals use data to monitor transfusion practices and provide feedback. There are many opportunities to enhance optimal uses of data to deliver effective quality improvement.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"1939-1951"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}